Literature DB >> 21315280

[11C]CURB: Evaluation of a novel radiotracer for imaging fatty acid amide hydrolase by positron emission tomography.

Alan A Wilson1, Armando Garcia, Jun Parkes, Sylvain Houle, Junchao Tong, Neil Vasdev.   

Abstract

INTRODUCTION: Fatty acid amide hydrolase (FAAH) is the enzyme responsible for metabolising the endogenous cannabinoid, anandamide, and thus represents an important target for molecular imaging. To date, no radiotracer has been shown to be useful for imaging of FAAH using either positron emission tomography (PET) or single photon emission computed tomography (SPECT). We here determine the suitability of a novel carbon-11-labeled inhibitor of FAAH via ex vivo biodistribution studies in rat brain in conjunction with pharmacological challenges.
METHODS: A potent irreversible inhibitor of FAAH, URB694, radiolabeled with carbon-11 in the carbonyl position ([(11)C]CURB), was administered to male rats via tail-vein injection. Rats were sacrificed at various time points postinjection, and tissue samples were dissected, counted and weighed. Specific binding to FAAH was investigated by pretreatment of animals with URB694 or URB597. For metabolism and mechanism of binding studies, whole brains were excised post-radiotracer injection, homogenised and extracted exhaustively with 80% aq. acetonitrile to determine the time course and fraction of radioactivity that was irreversibly bound to brain parenchyma.
RESULTS: Upon intravenous injection into rats, [(11)C]CURB showed high brain uptake [standard uptake value (SUV) of 1.6-2.4 at 5 min] with little washout over time, which is characteristic of irreversible binding. Highest uptake of radioactivity was seen in the cortex, intermediate in the cerebellum and lowest in the hypothalamus, reflecting the reported distribution of FAAH. Brain uptake of radioactivity was decreased in a dose-dependent manner by pretreatment with increasing amounts of URB694, demonstrating that binding was saturable. Pretreatment with the well-characterised FAAH inhibitor, URB597, reduced binding in all brain regions by 70-80%. Homogenised brain extraction experiments demonstrated unequivocally that [(11)C]CURB was irreversibly bound to FAAH.
CONCLUSIONS: The title radiotracer demonstrates favourable properties such as good brain uptake, regional heterogeneity and specificity of binding based on ex vivo biodistribution studies in conscious rat brain. [(11)C]CURB represents a highly promising radiotracer for the imaging of FAAH using PET.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21315280     DOI: 10.1016/j.nucmedbio.2010.08.001

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  34 in total

1.  The fatty acid amide hydrolase C385A variant affects brain binding of the positron emission tomography tracer [11C]CURB.

Authors:  Isabelle Boileau; Rachel F Tyndale; Belinda Williams; Esmaeil Mansouri; Duncan J Westwood; Bernard Le Foll; Pablo M Rusjan; Romina Mizrahi; Vincenzo De Luca; Qian Zhou; Alan A Wilson; Sylvain Houle; Stephen J Kish; Junchao Tong
Journal:  J Cereb Blood Flow Metab       Date:  2015-06-03       Impact factor: 6.200

2.  Mapping human brain fatty acid amide hydrolase activity with PET.

Authors:  Pablo M Rusjan; Alan A Wilson; Romina Mizrahi; Isabelle Boileau; Sofia E Chavez; Nancy J Lobaugh; Stephen J Kish; Sylvain Houle; Junchao Tong
Journal:  J Cereb Blood Flow Metab       Date:  2012-12-05       Impact factor: 6.200

3.  PET radiopharmaceuticals for probing enzymes in the brain.

Authors:  Jason P Holland; Paul Cumming; Neil Vasdev
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-04-09

Review 4.  (11)C[double bond, length as m-dash]O bonds made easily for positron emission tomography radiopharmaceuticals.

Authors:  Benjamin H Rotstein; Steven H Liang; Michael S Placzek; Jacob M Hooker; Antony D Gee; Frédéric Dollé; Alan A Wilson; Neil Vasdev
Journal:  Chem Soc Rev       Date:  2016-08-22       Impact factor: 54.564

5.  Inhibition of fatty acid amide hydrolase by BIA 10-2474 in rat brain.

Authors:  Junchao Tong; Romina Mizrahi; Sylvain Houle; Stephen J Kish; Isabelle Boileau; Jose Nobrega; Pablo M Rusjan; Alan A Wilson
Journal:  J Cereb Blood Flow Metab       Date:  2016-10-01       Impact factor: 6.200

Review 6.  Using molecular imaging to understand early schizophrenia-related psychosis neurochemistry: a review of human studies.

Authors:  Christin Schifani; Sina Hafizi; Tania Da Silva; Jeremy Joseph Watts; M Saad Khan; Romina Mizrahi
Journal:  Int Rev Psychiatry       Date:  2017-12-08

7.  Development and characterization of a promising fluorine-18 labelled radiopharmaceutical for in vivo imaging of fatty acid amide hydrolase.

Authors:  Oleg Sadovski; Justin W Hicks; Jun Parkes; Roger Raymond; José Nobrega; Sylvain Houle; Mariateresa Cipriano; Christopher J Fowler; Neil Vasdev; Alan A Wilson
Journal:  Bioorg Med Chem       Date:  2013-05-07       Impact factor: 3.641

8.  Radiosynthesis and ex vivo evaluation of [(11)C-carbonyl]carbamate- and urea-based monoacylglycerol lipase inhibitors.

Authors:  Justin W Hicks; Jun Parkes; Junchao Tong; Sylvain Houle; Neil Vasdev; Alan A Wilson
Journal:  Nucl Med Biol       Date:  2014-05-10       Impact factor: 2.408

Review 9.  11CO2 fixation: a renaissance in PET radiochemistry.

Authors:  Benjamin H Rotstein; Steven H Liang; Jason P Holland; Thomas Lee Collier; Jacob M Hooker; Alan A Wilson; Neil Vasdev
Journal:  Chem Commun (Camb)       Date:  2013-05-14       Impact factor: 6.222

10.  Fatty Acid Amide Hydrolase Binding in Brain of Cannabis Users: Imaging With the Novel Radiotracer [11C]CURB.

Authors:  Isabelle Boileau; Esmaeil Mansouri; Belinda Williams; Bernard Le Foll; Pablo Rusjan; Romina Mizrahi; Rachel F Tyndale; Marilyn A Huestis; Doris E Payer; Alan A Wilson; Sylvain Houle; Stephen J Kish; Junchao Tong
Journal:  Biol Psychiatry       Date:  2016-04-25       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.